LONDON, Dec. 12, 2018 (GLOBE NEWSWIRE) -- Visiongain report says: Global Ophthalmic Drugs Market Set To Grow To $29bn By 2022.
Visiongain has launched a new pharma report entitled Global Ophthalmic Drugs Market Forecast 2018-2028: Dry Eye, Glaucoma Drugs, Retinal Disorders Drugs and Allergic, Inflammatory & Infective Drugs.
To download sample pages of this critical report please click here: https://www.visiongain.com/report/global-ophthalmic-drugs-market-forecast-2018-2028/
Ophthalmic pharmaceuticals are pharmaceutical agents used to treat eye diseases, such as glaucoma, age-related macular degeneration (AMD), diabetic retinopathy, ocular allergies, infections, inflammatory conditions and dry eye. A specialist sector within the overall pharmaceutical industry, the ophthalmic drugs market is dominated by a relatively small number of companies. The market is relatively mature though with opportunities for growth in key therapeutic areas.
For full TOC please click on: https://www.visiongain.com/report/global-ophthalmic-drugs-market-forecast-2018-2028/
The lead analyst of the report commented, “For many indications, the advantages of pharmaceutical treatment far outweigh the benefits offered by alternative treatments such as surgery. As glaucoma, retinal disorders, inflammatory conditions and moderate to severe dry eye require management by medical professionals, the preferred treatment will be largely guided by clinical considerations rather than competition between alternative treatments.
Gene therapies and other regenerative medicine approaches to ophthalmic diseases may become effective substitutes towards the end of the forecast period. The area of gene therapy is still in its infancy with only a handful of currently marketed products. There is much research interest in gene therapies for conditions such as Leber’s congenital amaurosis and retinitis pigmentosa.”
To request your free report overview please email Sara on sara.peerun@visiongain.com or call her on +44 207 5499987
Leading companies featured in the report include Novartis, Regeneron, Allergan, Roche, Valeant, Santen, Bayer, Pfizer, Senju
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 207 5499987
About visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.